Patents by Inventor Erin F. Dimauro

Erin F. Dimauro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirotricycle RIPK1 inhibitors and methods of uses thereof
    Patent number: 12180226
    Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: December 31, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20240228506
    Abstract: Described herein are compounds of Formula II, or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: April 21, 2022
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Erin F. DiMauro, Xavier Fradera, Peter H. Fuller, Min Lu, Joey L. Methot, Matthew J. Mitcheltree, Andrew J. Musacchio, Phieng Siliphaivanh, Jing Su
  • PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240208986
    Abstract: Described herein are compounds of Formula I: (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Joanna L. Chen, Erin F. DiMauro, Kevin D. Dykstra, Xavier Fradera, Peter H. Fuller, Charles A. Lesburg, Min Lu, Joey L. Methot, Matthew J. Mitcheltree, Jing Su
  • ARYL ETHER COMPOUNDS AS TEAD MODULATORS
    Publication number: 20240083903
    Abstract: The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jongwon Lim, Vladimir Simov, Brandon A. Vara, Charles S. Yeung, Sebastian E. Schneider, Erin F. DiMauro
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20240025912
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: May 17, 2023
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Joanna L. Chen, Yi-Heng Chen, Erin F. DiMauro, Min Liu, Joey L. Methot, Andrew J. Musacchio, Anandan Palani, Barbara Pio, Lorena Rico Duque, Phieng Siliphaivanh, Brandon A. Vara
  • SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF
    Publication number: 20230159558
    Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: October 25, 2022
    Publication date: May 25, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9776995
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: October 3, 2017
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Erin F. DiMauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Holly L. Deak
  • Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
    Patent number: 9663508
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Amgen Inc.
    Inventors: Howard Bregman, Nagasree Chakka, Erin F. Dimauro, Hua Gao, Hakan Gunaydin, Hongbing Huang, Philip R. Olivieri, Laurie Schenkel, Matthew Weiss
  • Quinazolinone compounds and derivatives thereof
    Patent number: 9505749
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: November 29, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9458152
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgram, Hanh Nho Nguyen, Emily Anne Peterson, Karina R. Vaida, Brian Sparling
  • Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors
    Publication number: 20160214971
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Application
    Filed: October 1, 2014
    Publication date: July 28, 2016
    Applicant: One Amgen Center Drive
    Inventors: Howard BERGMAN, Nagasree CHAKKA, Erin F. DIMAURO, Hau GAO, Hakan GUNAYDIN, Homgbing HUANG, Philip R. OLIVIERI, Laurie SCHENKEL, Matthew WEISS
  • Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
    Patent number: 9346798
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 24, 2016
    Assignee: AMGEN INC.
    Inventors: Christiane Boezio, Alessandro Boezio, Howard Bregman, Nagasree Chakka, James R. Coats, Katrina Woodin Copeland, Erin F. Dimauro, Thomas Dineen, Hua Gao, Daniel La, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss
  • Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors
    Publication number: 20160137636
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 19, 2016
    Inventors: Matthew WEISS, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Isaac E. MARX, Hanh Nho NGUYEN, Emily Anne PETERSON, Holly L. DEAK
  • Oxazolidinone compounds and derivatives thereof
    Patent number: 9340549
    Abstract: Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 17, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Hongbing Huang, Xin Huang, Matthew W. Martin, Vinod F. Patel
  • Carboxamides as inhibitors of voltage-gated sodium channels
    Patent number: 9334269
    Abstract: The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: May 10, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Bingfan Du, Hanh Nho Nguyen, Xiao Mei Zheng
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20160046626
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 18, 2016
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRAM, Hanh Nho NGUYEN, Emily Anne PETERSON, Karina R. VAIDA, Brian SPARLING
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9212182
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgrim, Hanh Nho Nguyen, Emily Peterson, Karina Romero, Brian Sparling
  • Quinazolinone Compounds and Derivatives Thereof
    Publication number: 20150225396
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: August 27, 2013
    Publication date: August 13, 2015
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • Bicyclic aryl and heteroaryl sodium channel inhibitors
    Patent number: 9012443
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: April 21, 2015
    Assignee: Amgen Inc.
    Inventors: Christiane Boezio, Howard Bregman, James R. Coats, Erin F. Dimauro, Thomas Dineen, Bingfan Du, Russell Graceffa, Charles Kreiman, Daniel La, Isaac E. Marx, Nagasree Chakka, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss, Katrina W. Copeland, Holly L. Deak, Alessandro Boezio
  • DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS
    Publication number: 20150057271
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: February 12, 2013
    Publication date: February 26, 2015
    Inventors: Christiane Boezio, Alessandro Boezio, Howard Bregman, Nagasree Chakka, James R. Coats, Katrina Woodin Copeland, Erin F. Dimauro, Thomas Dineen, Hua Gao, Daniel La, Isaac E. Marx, Hanh Nho Nguyen, Emily Anne Peterson, Matthew Weiss